{"id":61557,"date":"2026-03-27T15:21:05","date_gmt":"2026-03-27T07:21:05","guid":{"rendered":"https:\/\/flcube.com\/?p=61557"},"modified":"2026-03-27T15:21:07","modified_gmt":"2026-03-27T07:21:07","slug":"novo-nordisks-awiqli-wins-fda-approval-worlds-first-once-weekly-basal-insulin-for-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61557","title":{"rendered":"Novo Nordisk’s Awiqli Wins FDA Approval \u2013 World’s First Once-Weekly Basal Insulin for Type 2 Diabetes"},"content":{"rendered":"\n

Novo Nordisk (NYSE: NVO<\/a>)<\/strong> announced FDA approval<\/strong> for Awiqli (insulin icodec)<\/strong>, becoming the world’s first and currently only once-weekly long-acting basal insulin<\/strong> for improving glycemic control in adults with type 2 diabetes (T2D)<\/strong> as an adjunct to diet and exercise. The approval, based on the ONWARDS Phase IIIa program<\/strong> demonstrating non-inferior A1C reduction vs. daily basal insulin<\/strong>, follows earlier approvals in China (May 2024), EU, Canada, Australia, Japan, and Switzerland<\/strong>, though the FDA rejected the type 1 diabetes indication in July 2024<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>U.S. Food and Drug Administration (FDA)<\/td><\/tr>
Approval Type<\/strong><\/td>Marketing authorization<\/td><\/tr>
Product<\/strong><\/td>Awiqli (insulin icodec)<\/td><\/tr>
Developer<\/strong><\/td>Novo Nordisk (NYSE: NVO)<\/td><\/tr>
Indication<\/strong><\/td>Type 2 diabetes only<\/strong> \u2013 glycemic control adjunct to diet\/exercise<\/td><\/tr>
Dosing<\/strong><\/td>Once-weekly<\/strong> \u2013 first and only long-acting basal insulin with weekly frequency<\/td><\/tr>
Global Status<\/strong><\/td>Approved: China, EU, Canada, Australia, Japan, Switzerland<\/strong> (T1D + T2D); FDA: T2D only<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Evidence: ONWARDS Phase IIIa Program<\/h2>\n\n\n\n
Parameter<\/th>Awiqli Performance<\/th>Comparator<\/th>Clinical Significance<\/th><\/tr><\/thead>
Patient Population<\/strong><\/td>2,680 adults with inadequately controlled T2D<\/td>\u2014<\/td>Representative real-world population<\/td><\/tr>
Primary Endpoint<\/strong><\/td>Glycated hemoglobin (A1C) reduction<\/strong><\/td>Once-daily basal insulin<\/td>Non-inferior glycemic control<\/strong><\/td><\/tr>
Dosing Frequency<\/strong><\/td>Once weekly<\/strong><\/td>Once daily<\/td>83% fewer injections<\/strong> \u2013 potential adherence advantage<\/td><\/tr>
Safety Profile<\/strong><\/td>Consistent with daily basal insulin analogs<\/td>\u2014<\/td>No new safety signals; hypoglycemia rates comparable<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context & Market Impact<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
Basal Insulin Market<\/strong><\/td>$10+ billion globally<\/strong>; dominated by glargine (Lantus)<\/strong>, detemir (Levemir)<\/strong>, degludec (Tresiba)<\/strong> \u2013 all daily dosing<\/strong>; Awiqli’s weekly convenience<\/strong> disrupts standard of care<\/td><\/tr>
Adherence Advantage<\/strong><\/td>~300 fewer injections annually<\/strong> vs. daily basal; addresses “injection fatigue”<\/strong> and treatment discontinuation<\/strong> \u2013 major unmet need in T2D management<\/td><\/tr>
Type 1 Diabetes Limitation<\/strong><\/td>FDA rejection July 2024<\/strong> \u2013 restricts label to T2D only; T1D opportunity lost<\/strong> vs. EU\/China approvals; may require additional cardiovascular outcomes data<\/td><\/tr>
Novo Nordisk Portfolio Synergy<\/strong><\/td>Complements Ozempic\/Wegovy (GLP-1)<\/strong> franchise; Awiqli + GLP-1 combination<\/strong> potential for comprehensive T2D management<\/td><\/tr>
Pricing Strategy<\/strong><\/td>Expected premium to daily basal insulins<\/strong> (~20\u201330%) \u2013 justified by convenience and adherence benefits; formulary negotiations<\/strong> critical for U.S. access<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n